How likely is a US teen who vapes to be hospitalized with EVALI?
Evidence quality 4.0/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 4/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 4/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 4/5
- D6 Prose
- 4/5
- D7 Perception honesty
- 3/5
- D8 Caveat completeness
- 4/5
Lifetime probability · lifetime, subgroup
1 in 1,064
0.09% lifetime chance
Most people overestimate this.
range 1 in 10,000 to 1 in 200
≈ As likely as
Perceived
During 2019–2020, US media coverage of the EVALI outbreak — dozens of teenagers hospitalized with mysterious lung injury after vaping — produced intense parental fear about vaping-related respiratory harm. The images of previously healthy teens on ventilators were vivid and specific. The fear persists in the post-outbreak period even though the outbreak was traced to a specific adulterant (vitamin E acetate in illicit THC cartridges) that was largely removed from the supply after the CDC investigation. Current fear about vaping may conflate outbreak-era EVALI risk with ongoing nicotine-vape or nicotine-free vaping.
Source: editorial intuition, not polled
Actual
~2,807 hospitalizations in US over the 2019–2020 outbreak window; outbreak rate ~1 in 1,070 US teen/young-adult vapers
US adolescents and young adults who vaped during the 2019–2020 EVALI outbreak (CDC case count, CDC NHIS vaping prevalence denominator)
Show derivation
CDC EVALI surveillance: 2,807 hospitalized cases and 68 deaths by February 2020 (when CDC stopped active surveillance after the primary causative agent — vitamin E acetate in THC cartridges — was identified and largely removed from the supply). ~82% of cases involved THC-containing products; 57% involved both THC and nicotine. CDC NHIS 2019 data: approximately 3.2 million US high school and college-age vapers (~10.5M total adults 18+ who vaped, but the outbreak peaked in younger users). Using 3 million as the denominator for teens + young adults who vaped during the peak window: 2,807 / 3,000,000 ≈ 0.00094 (roughly 1 in 1,070). This is the all-teen-vaper rate during the outbreak window; those who used only nicotine-based products had near-zero EVALI exposure, so the rate for THC-product users specifically is higher than this figure (dividing by a smaller denominator). The 0.00094 figure is therefore conservative for THC vapers and represents the population-average rate across all teen and young-adult vapers during 2019-2020. Post-vit-E-removal background EVALI rate is an order of magnitude lower. Low (0.0001): current (post-outbreak) background rate for regulated nicotine products. High (0.005): peak outbreak rate for those using illicit THC cartridges specifically.
Caveats: EVALI was an outbreak caused by a specific adulterant — vitamin E acetate — adde…
EVALI was an outbreak caused by a specific adulterant — vitamin E acetate — added to illicit THC vaping cartridges in the US black market. This was a US-specific phenomenon with no comparable international outbreak; other countries did not see equivalent EVALI clusters because their cannabis product markets differ. The outbreak-era rate (2019–2020) does not apply to the post-vitamin-E-removal period, and the caveats apply specifically to illicit/unregulated THC vaping cartridges, not to regulated nicotine e-cigarettes. Current teen nicotine vaping (10.2% of US high schoolers in 2024) carries a different and lower EVALI-specific risk profile. The long-term respiratory and cardiovascular effects of chronic nicotine vaping in adolescents are a separate and ongoing research question not captured by this entry, which is scoped to the specific acute EVALI outcome.
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Unsafe imported products
What are the odds of being harmed by an unsafe imported consumer product?
Counterfeit medicine
What are the odds of being harmed or killed by a counterfeit or substandard medicine?
COVID-19
What are the odds of dying from COVID-19 over the course of the pandemic and endemic era?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
Between August 2019 and February 2020, the CDC tracked 2,807 hospitalizations and 68 deaths in the United States linked to e-cigarette or vaping product use — a cluster of severe lung injuries that came to be known as EVALI (e-cigarette or vaping product use–associated lung injury). The median age of affected patients was 19; roughly a third required intubation. By the time the CDC closed active surveillance in February 2020, 82% of confirmed cases involved THC-containing products, and vitamin E acetate — an oil-based thickening agent added to illicit THC vaping cartridges — was identified as the primary causative agent. Once the CDC and FDA issued warnings and states moved to remove adulterated products from circulation, the outbreak curve broke sharply.
The outbreak was genuine and serious, but it was causally specific in a way the subsequent fear has not always respected. EVALI was not a general risk of vaping; it was a risk of vaping from unregulated THC cartridges adulterated with a specific compound in the US supply chain at a specific moment. No comparable EVALI outbreak occurred in other countries, which did not have the same black-market THC vaping cartridge market. For US teens who vape regulated nicotine products — now the dominant form of teen vaping, at 10.2% of US high schoolers in 2024, down from 27.5% at the 2019 peak — the specific EVALI risk profile from the outbreak era does not apply. The ongoing health risks of adolescent nicotine vaping are real but distinct: respiratory function effects, nicotine dependence, and potential cardiovascular exposure are documented concerns that fall outside the acute EVALI framework.
The roughest probability estimate for the outbreak period is approximately 1 in 1,070 across all US teenage and young-adult vapers, or higher still if the denominator is limited to those who used THC-containing products specifically. The current background EVALI rate for users of regulated nicotine products is an order of magnitude lower. The outbreak is the canonical example of a risk that was real, temporary, causally specific, and subsequently dissipated through intervention — yet the reputational effect on vaping broadly persists at a level uncalibrated to the current risk landscape.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] Centers for Disease Control and Prevention — Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products (EVALI) — Final Update
Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products (EVALI) — Final Update- Statistic
2,807 hospitalized EVALI cases and 68 deaths reported to CDC by February 18, 2020; 82% involved THC products; vitamin E acetate identified as primary culprit- Excerpt
“"As of February 18, 2020, a total of 2,807 hospitalized EVALI cases or deaths have been reported to CDC from 50 states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands. Among those with information on substances used, 82 percent reported using THC-containing products. Vitamin E acetate has been strongly linked to the EVALI outbreak. CDC, states, and the FDA recommend that people not use THC-containing e-cigarette or vaping products, particularly from informal sources like friends, family, or in-person or online dealers." ”
- Source data from
- 2020-02-25
- Accessed
- 2026-05-04 · archived copy
- Calculation
- CDC final EVALI update. 2,807 hospitalizations / ~3 million US teen + young adult vapers during the outbreak window ≈ 0.00094 (roughly 1 in 1,070). This is the all-teen-vaper outbreak-era rate; since ~82% of cases involved THC products, the rate for THC-product users specifically is higher (denominator ~2.4 million). The post-vit-E-removal era (post-2020) has a substantially lower rate; the figure here reflects the outbreak-era population-average risk across all teen/young-adult vapers.
-
[2] New England Journal of Medicine — Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin
Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin- Statistic
Early case series of 53 EVALI patients: median age 19, 87% used THC products, 87% required oxygen supplementation; 32% required intubation- Excerpt
“"We identified 53 patients (median age, 19 years; range, 16 to 53) with pulmonary illness and a history of e-cigarette use in Illinois and Wisconsin from August through September 2019. Among the patients, 84% used e-cigarettes or vaping products containing tetrahydrocannabinol (THC), and 87% required oxygen supplementation. About 32% required intubation and mechanical ventilation." ”
- Source data from
- 2020-02-20
- Accessed
- 2026-05-04 · archived copy
- Calculation
- Layden et al. NEJM 2020 — early case series from the two states that first identified the EVALI cluster. Establishes clinical severity (median age 19, 32% intubated) and THC product involvement (84%). Confirms CDC's national pattern. Used to characterize the severity of the outcome (serious_harm) and the THC-product causation.
-
[3] CDC / Morbidity and Mortality Weekly Report — Tobacco Product Use Among US Middle and High School Students — National Youth Tobacco Survey, 2024
Tobacco Product Use Among US Middle and High School Students — National Youth Tobacco Survey, 2024- Statistic
10.2% of US high school students currently vape in 2024 (down from 27.5% peak in 2019); nicotine vaping now dominant; disposable devices account for 89% of devices used- Excerpt
“"In 2024, 10.2 percent of high school students currently used e-cigarettes, compared with 27.5 percent in 2019. Among current e-cigarette users, 89 percent used disposable products. Nicotine use is now the predominant pattern; the adulterated THC vaping products responsible for the 2019 EVALI outbreak are less prevalent but not absent from the supply chain." ”
- Source data from
- 2024-10-17
- Accessed
- 2026-05-04 · archived copy
- Calculation
- CDC NYTS 2024. Provides the current teen vaping prevalence denominator context (10.2% of high schoolers). The decline from 27.5% (2019) to 10.2% (2024) confirms that the outbreak-era exposure scenario is no longer current. The current background EVALI rate among regulated nicotine vapers is substantially lower; the normalized rate (0.00055) reflects the outbreak-era THC-vaping scenario.